Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea. (August 2015)

• Record Type: Journal Article
• Authors: Witjes, Han; Creinin, Mitchell D.; Sundström-Poromaa, Inger; Martin Nguyen, Allison; Korver, Tjeerd
• Is Part Of: European journal of contraception & reproductive health care. Volume 20:Number 4(2015:Aug.)
• Page Start: 296
• Page End: 307
• Publication Date: 2015-08
• Subjects: Contraception -- Periodicals; Reproductive health -- Periodicals; Generative organs, Female -- Periodicals; Contraception -- Periodicals; Reproductive Medicine -- Periodicals; 613.9
• DOI: 10.3109/13625187.2015.1016154
• Languages: English
• ISSNs: 1362-5187

Abstract

<abstract> <title>Abstract</title> <p> <bold>Objectives</bold> To compare premenstrual and menstrual symptoms in healthy women using nomegestrol acetate/17β-estradiol (NOMAC/E2) and drospirenone/ethinylestradiol (DRSP/EE) via the Moos Menstrual Distress Questionnaire Form C (MDQ-C).</p> <p> <bold>Methods</bold> Women completed the MDQ-C at baseline and after completion of cycles 1, 3, 6 and 13, for the premenstrual (four days before most recent flow) and menstrual (most recent flow) phases in two randomized controlled trials. Treatment effects of NOMAC/E2 and DRSP/EE on the <italic>t</italic>-scores of eight MDQ-C symptom domains from 3522 women were examined, and the effects of both treatments on the score for cramps from 1779 women with moderate to severe cramps at baseline. Longitudinal data analysis methods were applied in both analyses.</p> <p> <bold>Results</bold> NOMAC/E2 users experienced a significant improvement in Pain, Water Retention, Negative Affect, Impaired Concentration and Behaviour Change domain scores in the menstrual phase compared with DRSP/EE users (<italic>p</italic> < 0.001 for all comparisons). However, Arousal (emotional and mental) scores worsened with NOMAC/E2 but not with DRSP/EE. Women with moderate to severe cramps experienced an improvement in the cramps score with NOMAC/E2 and DRSP/EE.</p> <p> <bold>Conclusions</bold> NOMAC/E2 was effective in reducing most premenstrual and menstrual symptoms, and was associated with significantly greater improvements in many MDQ-C domain scores compared with DRSP/EE.</p> <p> <bold>(<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link>:</bold> NCT00413062 and NCT00511199).</p> </abstract>